The Medical Letter website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more      
The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1547
Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
The full article is available to subscribers Subscriber Login   

The FDA has approved inotuzumab ozogamicin (Besponsa – Pfizer), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults. It is the first CD22-directed antibody-drug conjugate to be approved in the US.

RELAPSED OR REFRACTORY ALL — Induction chemotherapy induces a complete remission in 60-90% of adults with newly-diagnosed ALL, but most of these patients will subsequently relapse. The goal for patients who do not respond to induction therapy and those who respond initially and then relapse is to achieve a complete remission, or close to it, in order to proceed to an allogeneic hematopoietic cell transplant (HCT), which can be curative.1

MECHANISM OF ACTION — The antibody-drug conjugate binds to CD22, which ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
Article code: 1547f
 Electronic, downloadable article - $25